Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

A Phase IIa, Double-blind, Randomized, 2-way Cross-over Study to Evaluate the Effect of a Single Dose of AZD1386 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity in GERD Patients With a Partial Response to PPI Treatment

The purpose of the study is to compare sensitivity of visceral pain in the esophagus using different pain stimuli.

Inclusion Criteria:

• Provision of signed informed consent form
• BMI 18.5-35.0, inclusive
• Continuous PPI treatment for GERD during the last 4 weeks

Exclusion Criteria:

• Patients that have not experienced any GERD symptoms improvement at all after PPI treatment
• Unstable or clinically significant disorders including cardiovascular, respiratory, renal, hepatic, metabolic, psychiatric, other gastrointestinal and esophageal disorders besides GERD
• Prior surgery of the upper GI tract